Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director | September 15, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date September 15, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectJames N. Wilson and Pamela D. Wilson Trust | 1,064,543 |
Last balance in matching sequence
After 2026-09-15 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-09-15 · Sale · Disposed 6,800 · Balance 1,067,743 F1: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction. F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $109.66 to $110.64 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F5: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Row 2 · 2026-09-15 · Sale · Disposed 400 · Balance 1,067,343 F1: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction. F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.665 to $111.095 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F5: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Row 3 · 2026-09-15 · Sale · Disposed 2,800 · Balance 1,064,543 F1: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction. F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.70 to $111.705 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F5: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectJames N. Wilson 2025 Grantor Retained Annuity Trust | 200,000 |
Reported balance
Holding disclosure · report date 2026-09-15 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 200,000 |
| Common StockSEC Table I · non-derivative | IndirectPamela D. Wilson 2025 Grantor Retained Annuity Trust | 200,000 |
Reported balance
Holding disclosure · report date 2026-09-15 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 200,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $109.66 to $110.64 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.665 to $111.095 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.70 to $111.705 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 16, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 2,800 | $111.70 | $312,770.92 |
DisclosureSEC source: 0001193125-26-393124 · ownership.xml · nonDerivative · entry 3 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Plan reported Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,064,543 F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.70 to $111.705 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F5 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 400 | $110.84 | $44,334.52 |
DisclosureSEC source: 0001193125-26-393124 · ownership.xml · nonDerivative · entry 2 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Plan reported Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,067,343 F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.665 to $111.095 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F5 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 6,800 | $110.27 | $749,834.64 |
DisclosureSEC source: 0001193125-26-393124 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Plan reported Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,067,743 F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $109.66 to $110.64 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F5 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 2,279 | $112.64 | $256,706.10 |
DisclosureSEC source: 0001193125-26-355562 · ownership.xml · nonDerivative · entry 3 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Plan reported Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,074,543 F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.51 to $112.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F5 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 4,668 | $111.44 | $520,213.59 |
DisclosureSEC source: 0001193125-26-355562 · ownership.xml · nonDerivative · entry 2 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Plan reported Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,076,822 F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.01 to $112.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F5 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 3,053 | $110.49 | $337,340.93 |
DisclosureSEC source: 0001193125-26-355562 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Plan reported Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,081,490 F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.00 to $110.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F5 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 22:38 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 1,978 | $89.49 | $177,007.46 |
DisclosureSEC source: 0001193125-26-308061 · ownership.xml · nonDerivative · entry 4 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Plan reported Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,084,543 F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction. F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $89.31 to $89.665 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F6 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 22:38 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 2,974 | $88.81 | $264,122.43 |
DisclosureSEC source: 0001193125-26-308061 · ownership.xml · nonDerivative · entry 3 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Plan reported Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,086,521 F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $88.24 to $89.17 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F6 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 22:38 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 3,969 | $87.74 | $348,222.60 |
DisclosureSEC source: 0001193125-26-308061 · ownership.xml · nonDerivative · entry 2 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Plan reported Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,089,495 F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $87.23 to $88.20 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F6 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 22:38 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 1,079 | $86.78 | $93,633.14 |
DisclosureSEC source: 0001193125-26-308061 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Plan reported Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,093,464 F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $86.20 to $87.18 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F6 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 5,823 | $83.57 | $486,632.77 |
DisclosureSEC source: 0001193125-26-275964 · ownership.xml · nonDerivative · entry 2 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Plan reported Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,094,543 F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.16 to $83.935 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F4 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 4,177 | $82.69 | $345,416.18 |
DisclosureSEC source: 0001193125-26-275964 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Plan reported Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,100,366 F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $82.13 to $83.125 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F4 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 27, 2026 Filed May 29, 2026 21:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 9,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-248953 · ownership.xml · nonDerivative · entry 3 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,104,543 F2 · kind: Transfer of shares without consideration to the James N. Wilson and Pamela D. Wilson Trust. F1 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 27, 2026 Filed May 29, 2026 21:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 9,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-248953 · ownership.xml · nonDerivative · entry 2 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James and Pamela Wilson Family Partners Disclosed balance after: 0 F2 · kind: Transfer of shares without consideration to the James N. Wilson and Pamela D. Wilson Trust. F1 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 27, 2026 Filed May 29, 2026 21:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 892,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-248953 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James and Pamela Wilson Family Partners Disclosed balance after: 9,011 F1 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 21, 2026 Filed May 26, 2026 21:36 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $59.69 | $0.00 |
DisclosureSEC source: 0001193125-26-239707 · ownership.xml · derivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2036-05-21 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-177404 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,095,532 F1 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 23:29 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-148488 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,097,532 F1 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 20:55 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-122139 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,102,532 F1 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| March 13, 2026 Filed Mar 18, 2026 00:03 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-111536 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,106,532 F1 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:45 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001193125-26-076999 · ownership.xml · derivative · entry 8 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:45 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 89,364 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-076999 · ownership.xml · nonDerivative · entry 4 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,134,532 F2 · kind: Transfer of shares without consideration to the James N. Wilson and Pamela D. Wilson Trust. F3 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:45 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 89,364 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-076999 · ownership.xml · nonDerivative · entry 3 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · kind: Transfer of shares without consideration to the James N. Wilson and Pamela D. Wilson Trust. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:45 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 10,636 | $36.48 | $388,001.28 |
DisclosureSEC source: 0001193125-26-076999 · ownership.xml · nonDerivative · entry 2 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,364 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options. The options subject to the net exercise were to expire on February 26, 2026. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:45 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 100,000 | $3.88 | $388,000.00 |
DisclosureSEC source: 0001193125-26-076999 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-321408 · ownership.xml · nonDerivative · entry 3 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Pamela D. Wilson 2025 Grantor Retained Annuity Trust. Disclosed balance after: 200,000 F4 · kind: Transfer of shares without consideration to Pamela D. Wilson 2025 Grantor Retained Annuity Trust. F5 · ownership.nature: On December 12, 2025, the Reporting Person contributed 200,000 shares to a grantor retained annuity trust for the benefit of Pamela D. Wilson, the Reporting Person and her two children. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-321408 · ownership.xml · nonDerivative · entry 2 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James N. Wilson 2025 Grantor Retained Annuity Trust. Disclosed balance after: 200,000 F2 · kind: Transfer of shares without consideration to James N. Wilson 2025 Grantor Retained Annuity Trust. F3 · ownership.nature: On December 12, 2025, the Reporting Person contributed 200,000 shares to a grantor retained annuity trust for the benefit of himself, Pamela D. Wilson and his two children. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-321408 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,045,168 F1 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 00:44 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0000950170-25-085764 · ownership.xml · derivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of June 10, 2025 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:14 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 7,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-010499 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,445,168 F1 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| January 22, 2025 Filed Jan 25, 2025 01:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 250,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000950170-25-008963 · ownership.xml · derivative · entry 6 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 22, 2025 Filed Jan 25, 2025 01:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 146,742 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-008963 · ownership.xml · nonDerivative · entry 4 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,452,968 F2 · kind: Transfer of shares without consideration to the James N. Wilson and Pamela D. Wilson Trust. F3 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| January 22, 2025 Filed Jan 25, 2025 01:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 146,742 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-008963 · ownership.xml · nonDerivative · entry 3 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 22, 2025 Filed Jan 25, 2025 01:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 103,258 | $59.03 | $6,095,319.74 |
DisclosureSEC source: 0000950170-25-008963 · ownership.xml · nonDerivative · entry 2 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,742 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on January 22, 2025. Read SEC document |
| January 22, 2025 Filed Jan 25, 2025 01:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 250,000 | $3.29 | $822,500.00 |
DisclosureSEC source: 0000950170-25-008963 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 21:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 7,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-141638 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,306,226 F1 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 23, 2024 Filed May 28, 2024 23:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-065537 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,314,026 F1 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 17, 2024 Filed May 21, 2024 22:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantEmployee stock option (right to buy) · Derivative | 80,000 | $0.00 Strike: $28.09 | $0.00 |
DisclosureSEC source: 0000950170-24-063131 · ownership.xml · derivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2034-05-16 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 17, 2024 over a one-year period. Read SEC document |
| November 13, 2023 Filed Nov 16, 2023 00:55 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-064309 · ownership.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,316,026 F1 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 19, 2023 Filed May 23, 2023 21:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 80,000 | $0.00 Strike: $24.10 | $0.00 |
DisclosureSEC source: 0000899243-23-013738 · doc4.xml · derivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-05-18 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 19, 2023 over a one-year period. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 300,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-022855 · doc4.xml · derivative · entry 6 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2023-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 168,181 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-022855 · doc4.xml · nonDerivative · entry 4 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,331,026 F2 · kind: Transfer of shares without consideration to the James N. Wilson and Pamela D. Wilson Trust. F3 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 168,181 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-022855 · doc4.xml · nonDerivative · entry 3 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,181 F2 · kind: Transfer of shares without consideration to the James N. Wilson and Pamela D. Wilson Trust. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 131,819 | $21.10 | $2,781,380.90 |
DisclosureSEC source: 0000899243-22-022855 · doc4.xml · nonDerivative · entry 2 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,181 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on June 14, 2022. The options subject to the net exercise were to expire on January 30, 2023. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 300,000 | $2.08 | $624,000.00 |
DisclosureSEC source: 0000899243-22-022855 · doc4.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 21:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 45,000 | $0.00 Strike: $20.84 | $0.00 |
DisclosureSEC source: 0000899243-22-020700 · doc4.xml · derivative · entry 2 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 45,000 shares Expires 2032-05-30 F2 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 31, 2022 over a one-year period. Read SEC document |
| February 02, 2022 Filed Feb 15, 2023 00:30 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005069 · doc5.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,319,026 Read SEC document |
| May 26, 2021 Filed May 28, 2021 21:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $21.45 | $0.00 |
DisclosureSEC source: 0000899243-21-021143 · doc4.xml · derivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 26, 2021 over a one-year period. Read SEC document |
| April 14, 2021 Filed Apr 17, 2021 01:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0000899243-21-016142 · doc4.xml · derivative · entry 6 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2021-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| April 14, 2021 Filed Apr 17, 2021 01:08 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 109,483 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-016142 · doc4.xml · nonDerivative · entry 4 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,174,845 F2 · kind: Transfer of shares without consideration to the James N. Wilson and Pamela D. Wilson Trust. F3 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.